// App-Quantinova.ai

e22030 : Biomarkers to predict the clinical efficacy of bevacizumab in advanced colorectal cancer: KRAS mutational status of circulating tumor cells.

Researchers

Presenter

  • Marco Danova

Principal Investigators

  • Giuditta Comolli

  • Giuliano Mazzini

  • Martina Torchio

  • Valerio Gristina

  • Alessandro Stefano Bertolini

Medical Centers

  • Microbiology and Virology, Biotechnology Laboratories, IRCCS San Matteo, Pavia, Italy

  • Medicina Interna ed Oncologia Medica Ospedale Civile di Vigevano Azienda Ospedaliera di Pavia, Vigevano, ItalyMolecular Genetic Institute, IGM-CNR, Pavia, ItalyMedical Oncology, Ospedale di Sondrio, Sondrio, Italy

  • Internal Medicine and Medical Oncology, Ospedale Civile, Vigevano, Italy

Locations

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Colorectal Cancer

Biomarkers

  • Circulating tumor cells

  • KRAS proto-oncogene, GTPase

Drug/Treatment

  • Bevacizumab

Outcome

  • Positive

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved